Diagnostic imaging and therapeutic agents to help identify and treat disease and improve patient care
Improved diagnostic information for better patient management
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe
Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia
Providing you with important information regarding our response to the C0VID-19 pandemic.
(updated 1/8/2021)
View a Lantheus webinar:
COVID-19: Clinical Experiences from the Front Line in NYC
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe
Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.